Search the Newsreel

We Think Crexendo's (NASDAQ:CXDO) Profit Is Only A Baseline For What They Can Achieve

Crexendo, Inc. (NASDAQ:CXDO) recently posted solid earnings, but the market appears to be overly pessimistic. Analysis shows that the company's statutory earnings are likely conservative due to a negative accrual ratio and the impact of unusual items. However, shareholder dilution from new share issuance …

Nexxen International (NEXN) Earnings Date and Reports 2026

Crexendo Inc (CXDO) (Q2 2026) Earnings Call Highlights: Revenue Surges 49% as Platform Wins ...

Crexendo reported strong Q2 2026 results with a 49% revenue increase to $24.6 million, driven by the ESI acquisition and growth in telecom services. The company achieved GAAP net income of $1.1 million and a substantial increase in new platform customers, securing 11 new …

Crexendo (CXDO) Q2 2026 Earnings Call Transcript

Crexendo reported strong Q2 2026 results with a 49% revenue increase to $24.6 million, driven by the ESI acquisition and growth in telecom services. The company achieved GAAP net income of $1.1 million and a substantial increase in new platform customers, securing 11 new …

Crexendo (CXDO) is an Incredible Growth Stock: 3 Reasons Why

Crexendo (CXDO) is identified as an incredible growth stock by Zacks' proprietary system, earning a favorable Growth Score and a top Zacks Rank. The company shows strong prospects with an expected EPS growth of 25% this year, crushing the industry average, and an impressive …

Xencor stock hits 52-week high at 21.99 USD

Xencor Inc. (XNCR) has reached a new 52-week high of $21.99, demonstrating a 41% year-to-date return and a 178.71% increase over the past year, reflecting strong investor confidence in the biotechnology company. This growth is attributed to its innovative work in engineered monoclonal antibodies …

Crexendo’s cloud communications platform reaches 8M users By Investing.com

Crexendo, Inc. announced its cloud communications platform now supports over 8 million users worldwide, adding approximately one million users in eight months. The platform has grown over 370% since Crexendo acquired NetSapiens in June 2021. The company's platform includes CAIRO, an AI receptionist and …

CXDO Looks 8.2% Undervalued on GF Value™

Crexendo Inc (NASDAQ: CXDO) is currently deemed 8.2% undervalued by GuruFocus' GF Value™, with a current price of $6.30 against an intrinsic value of $6.86. The company recently announced its AI-driven UCaaS platform surpassed 8 million global users, reflecting significant growth. While insider selling …

Crexendo Cloud Platform Adds About 1M Users Worldwide in 8 Months

Crexendo (NASDAQ: CXDO) announced that its AI-enhanced UCaaS cloud communications platform now supports over 8 million users worldwide, an increase of approximately one million users since late 2025. The platform's user base has grown over 370% since the June 2021 acquisition of NetSapiens. The …

H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy

H.C. Wainwright maintained a Buy rating and a $74.00 price target for Xenon Pharmaceuticals (NASDAQ: XENE), citing the FDA's lack of concerns regarding their pre-NDA meeting and the company's belief that their drug package supports approval of all four doses. The stock has seen …

HC Wainwright Issues Positive Outlook for XENE Earnings

HC Wainwright has revised its earnings outlook for Xenon Pharmaceuticals (NASDAQ:XENE), predicting reduced losses for Q3 2026 and subsequent fiscal years, and maintaining a "Buy" rating with a $74 price target. The biopharmaceutical company recently surpassed analyst expectations for its quarterly loss. Despite these …

Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss

Xencor (XNCR) recently reported a narrower quarterly net loss, reinforcing positive sentiment and leading to significant share price returns over the last month and year. Despite negative 3- and 5-year returns, the company is considered 24.3% undervalued with a fair value of $28.50 compared …

Nexxen to Stream Three Executive Fireside Chats Online

Nexxen International Ltd. announced that its executive management and investor relations teams will participate in three upcoming financial conferences: the Canaccord Genuity Annual Growth Conference on August 12, the Rosenblatt Annual Technology Summit on August 18, and the Citi Global TMT Conference on September …

What’s Behind Xenia Hotels & Resorts (XHR) Stock’s Latest Move?

Crexendo posts investor presentation to website under Regulation FD

Crexendo (CXDO) announced it has posted an investor presentation on its investor relations website, www.crexendo.com

Form 8K Crexendo For: 10 August By Investing.com

This article reports on a Form 8K filing by Crexendo for August 10th. The brief piece includes the company's stock symbol CXDO and its current performance of +2.06%. It also shows general market data for various indices, commodities, bonds, and shares.

Brokers Issue Forecasts for XENE Q1 Earnings

Crexendo: Positive Q2 Results And Outlook Could Drive Strong Stock Gains (NASDAQ:CXDO)

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

Quantinno Capital Management LP significantly increased its stake in Xenon Pharmaceuticals Inc. by 125.1% in the first quarter, acquiring an additional 30,816 shares. The biopharmaceutical company, which has no product sales, reported a narrower-than-expected quarterly loss of $1.11 per share. Analyst sentiment remains largely …

Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results

Xencor, Inc. (NASDAQ:XNCR) recently released a strong quarterly report, with revenue significantly beating expectations and losses being smaller than predicted. This positive performance has led analysts to upgrade their revenue estimates for 2026 and reduce loss estimates, though the consensus price target remains unchanged. …

Crexendo Inc (CXDO) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Crexendo Inc (CXDO), indicating a current earnings forecast score of 8.00 and an average price target of $9.00 based on 6 analysts. Most analysts recommend a "Buy" for CXDO, with an expected revenue of $25.14M for the …

Price to earnings forward of Xenitra Limited – ASX:XEN

FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals reported a net loss of US$110.74 million in Q2 2026, but its successful pre-NDA meeting with the FDA for azetukalner and a US$1.20 billion cash balance position it for potential regulatory milestones. The company is on track to submit an NDA for …

How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit

Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor's …

Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside

Xencor, Inc. (XNCR) has seen its average 12-month price target raised from $28.75 to $29 by 12 analysts, implying a 45% potential upside from its Aug. 6 closing price. The consensus rating for the stock remains "Buy" among 14 analysts, with 12 recommending a …

Xenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside

Xenon Pharmaceuticals Inc. (XENE) has seen its average 12-month price target increased by analysts to $81.21, up from $80.8, with a potential upside of approximately 26% based on its recent closing price. The consensus rating remains a "Buy" from 18 covering analysts, indicating strong …

Nexxen International Ltd. Sponsored ADR (NASDAQ:NEXN) Receives Consensus Rating of "Moderate Buy" from Analysts

Nexxen International Ltd. (NASDAQ:NEXN) has received a "Moderate Buy" consensus rating from analysts, with nine buy ratings and one hold, and an average 12-month price target of $11.61. The stock has shown strong momentum, nearing its 52-week high, despite recent insider selling by the …

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Xencor (NASDAQ:XNCR) from "strong sell" to "hold" after the company reported better-than-expected quarterly results, including a smaller loss per share and significantly higher revenue than anticipated. Despite the upgrade and several bullish analyst price targets, the broader analyst consensus …

Xencor Inc (XNCR) Stock News Today

Zacks Industry Outlook WPP, Nexxen and Quad/Graphics

The Zacks Advertising and Marketing industry is facing challenges from rising costs and inflation but is adapting through increased digital marketing services and the use of artificial intelligence. WPP Plc, Nexxen International Ltd., and Quad/Graphics, Inc. are highlighted as companies navigating these challenges with …

XENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63

Wedbush has increased its target price for Xenon Pharmaceuticals Inc. (XENE.O) shares to $71, up from the previous target of $63. This adjustment suggests an improved outlook from the analyst firm for the pharmaceutical company's stock. The information was released by Reuters on August …

Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss

Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business …

Xenetic partner receives Israeli approvals for lymphoma study

Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in …

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal …

Nexxen International Ltd (NEXN) Stock News Today

This article provides the latest stock news for Nexxen International Ltd (NEXN) on TradingKey. It displays current stock performance, market capitalization, and P/E ratio. The content indicates that more news will be coming soon for the company.